arrow
V

Vinod Pullarkat

City Of Hope National Medical Center
H指数:53
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy

B细胞活化因子受体在B淋巴母细胞白血病中的表达:流式细胞术分析及其靶向治疗意义

2026-08-210
PRE
Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia
2026-08-150
PRE
Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation

无残疾生存:老年异基因造血细胞移植的一种新型疾病终点

2026-03-280
PRE
Impact of Itacitinib Exposure on Immune Reconstitution and Cytokine Profile Following HLA-Matched Allogeneic Hematopoietic Cell Transplantation (HCT) with Tacrolimus, Sirolimus, and Itacitinib GVHD Prophylaxis
2026-02-030
PRE
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

异基因造血干细胞移植(allo-HCT)在采用氟达拉滨/美法仑(Fludarabine/Melphalan)预处理和他克莫司/西罗莫司(Tacrolimus/Sirolimus)移植物抗宿主病(GVHD)预防方案的急性髓系白血病(AML)中的长期生存结局。

2025-11-180
OAAI
Pulmonary manifestations during neutrophil engraftment in recipients of allogeneic hematopoietic cell transplantation for myelofibrosis

异基因造血细胞移植治疗骨髓纤维化受者中中性粒细胞植入期间的肺部表现

2025-09-240
OA
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in new era: A CIBMTR study

异基因造血细胞移植在新时代晚期系统性肥大细胞增生症中的应用:一项CIBMTR研究

2025-09-220
PRE
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML

在IDH-2突变急性髓系白血病异基因造血细胞移植后使用enasidenib维持治疗的试验

2025-09-190
PRE
The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden

细胞减灭术对高肿瘤负荷复发或难治性B-ALL患者博纳吐莫单抗疗效的影响

2025-09-090
PRE
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

接受维奈克拉联合阿扎胞苷治疗的患者与仅接受阿扎胞苷治疗的患者,其结局比较,按高龄和急性髓系白血病复合模型分层。

Leukemia
IF13.4
2025-09-050
OAAI
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia

靶向治疗和免疫疗法在TP53突变急性淋巴细胞白血病患者中的疗效

2025-09-010
PRE
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

社会决定因素对成人复发/难治性B细胞急性淋巴细胞白血病患者brexucabtagene autoleucel治疗结局的影响

2025-08-230
OAAI
Outcomes After Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Renal Impairment

基于美法仑的减低强度异基因造血细胞移植在肾功能不全患者中的结局

2025-07-010
PRE